Focused radiation, no incision: radiosurgery eases severe treatment-resistant depression

A form of brain surgery that involves no scalpel, no drill and no implanted hardware is emerging as a potential option for some of the most stubborn cases of depression in psychiatry. At the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, researchers reported that stereotactic radiosurgical capsulotomy, a technique that uses highly focused beams of radiation to create a minute lesion deep within the brain, produced substantial and durable reductions in depressive symptoms and suicidal thinking among patients whose illness had resisted every conventional therapy. The findings come from a prospective observational study of 20 patients treated at Vanderbilt University Medical Center, and they arrive with both excitement and a strong note of caution from the investigators themselves.

The population studied represents the hardest edge of a condition that affects millions. Treatment-resistant depression is generally defined as depression that fails to improve adequately after at least two antidepressant treatments, and it is estimated to affect roughly three in ten people with the illness. For these patients, the remaining options are limited and burdensome: additional medication trials, ketamine-based therapies, electroconvulsive therapy, or invasive ablative procedures such as radiofrequency ablation. Each carries meaningful risks of side effects, and many demand repeated sessions or actual surgery. It is against this backdrop that the Vanderbilt team, working with colleagues at the University of South Florida and Tampa General Hospital, explored whether the precision of modern radiation therapy could offer something new.

Stereotactic radiosurgical capsulotomy works by targeting a small region of the anterior limb of the internal capsule, a brain pathway long implicated in mood regulation and obsessive-compulsive symptoms. Capsulotomy itself has a decades-long history in the treatment of severe psychiatric illness, but the radiosurgical version has been studied almost exclusively in severe, treatment-resistant obsessive-compulsive disorder rather than depression. The procedure requires no incision and no implanted device. Instead, patients are fitted with a mask that immobilizes the head, and a linear accelerator delivers cross-fired radiation beams that converge on a target only millimeters wide. The goal, as lead author Dr. Mohamed Khattab, a radiation oncologist at the University of South Florida and Tampa General Hospital, explained, is to interrupt a circuit contributing to severe, persistent symptoms while sparing the surrounding brain tissue.

The new study builds on a small 2022 pilot in which three patients underwent frameless stereotactic radiosurgical capsulotomy for refractory depression. In that initial report, all three experienced reductions or complete resolution of suicidal thoughts, with no observed cognitive decline or neurologic side effects. Encouraged by those results, the team expanded the program. Between 2020 and 2025, twenty patients with treatment-resistant depression, ten of whom also carried a diagnosis of comorbid obsessive-compulsive disorder, were treated at Vanderbilt for medical necessity after review by a multidisciplinary team spanning psychiatry, neurosurgery and radiation oncology. The severity of their histories is difficult to overstate: every patient had previously received cognitive therapy and multiple medications, and many had failed to improve with ketamine, transcranial magnetic stimulation, electroconvulsive therapy, or some combination of these.

The results, measured with standardized instruments and quarterly evaluations over a median follow-up of 38.6 months, were striking. Among the 18 patients evaluated for depression symptoms, the average score on the Beck’s Depression Inventory, a widely used self-report measure, fell by 53 percent from before radiosurgery to the point of greatest improvement. Eleven patients, or 61 percent, saw their scores drop by at least half, and 16 patients, or 89 percent, showed some numerical improvement. Crucially, the benefits did not evaporate with time. At the most recent follow-up, the average depression score remained 47 percent below the pretreatment baseline, half of the evaluated patients still met the threshold for a treatment response, and 89 percent remained improved compared with where they started.

Perhaps the most dramatic number concerned suicidal ideation. Before treatment, 14 of the 20 patients, or 70 percent, reported active thoughts of suicide. After radiosurgery, exactly one patient, or 5 percent, did. For a population in which many individuals were living with persistent, treatment-refractory suicidal thinking, that shift represents a potentially life-altering outcome, and it is the aspect of the study that outside experts have flagged as most compelling. Dr. Khattab noted that these were patients whose depression had not improved after several other treatments and that many were living with active thoughts of suicide, yet after treatment the majority experienced meaningful reductions in both depressive symptoms and suicidal thoughts.

Equally important for a procedure that targets the brain is what did not happen. Researchers found no overall evidence of cognitive decline. Scores on the Montreal Cognitive Assessment were stable or numerically higher after treatment, with all 20 patients showing stable or improved scores at their point of greatest improvement and 19 of 20 doing so at last follow-up. The team also observed no neurologic deficits, no apathy and no personality changes, outcomes that address a common and understandable fear about any intervention involving brain tissue. Three patients did experience moderate treatment-related side effects consisting of headache or dizziness, and two of those also showed larger-than-intended tissue changes on imaging, but all recovered fully with steroid treatment.

Dr. Khattab and his colleagues are careful to frame the findings within their limits. The study was small and lacked a comparison group, which means it cannot establish that radiosurgery itself caused the improvements; spontaneous remission, placebo effects, the intense clinical attention participants received, or regression to the mean in patients selected at their lowest point could all contribute. Larger, controlled studies will be needed to confirm the results and to clarify which patients are most likely to benefit and what risks may emerge over longer horizons. Caution is especially warranted, the researchers argue, given the troubled history of ablative psychosurgery. Modern stereotactic techniques are vastly more precise than the procedures of the mid-twentieth century, but radiosurgical capsulotomy still demands rigorous patient selection, thorough informed consent and specialized multidisciplinary expertise. Although the linear accelerator technology used to deliver the treatment is widely available in radiation oncology departments, Dr. Khattab emphasized that the procedure itself should remain confined to experienced teams.

That sentiment is echoed within the radiation oncology community. Dr. Markus Bredel, co-chair of ASTRO’s Functional Radiation Medicine Task Force and chair of radiation oncology at the University of Miami Sylvester Comprehensive Cancer Center, described the study as important because it evaluates a highly targeted, incisionless approach in patients who had already tried multiple therapies while also tracking cognition and safety over time. The reduction in suicidal ideation, he observed, is striking, but the findings should be viewed as early evidence from a specialized, multidisciplinary program, and larger studies will be needed before the approach can be understood as part of routine care.

Even with those caveats, the study signals a notable convergence between radiation medicine and psychiatry. It suggests that the same physics that allows clinicians to ablate a tumor with submillimeter accuracy can be redirected toward dysfunctional neural circuits, offering an incisionless alternative for patients who have exhausted pharmacologic, stimulation-based and psychotherapeutic options. For the field, the immediate task is rigorous replication: randomized or matched controlled trials, longer follow-up, standardized target definition and clearer criteria for candidate selection. For patients who have lived for years with severe depression despite trying nearly every available treatment, as Dr. Khattab put it, the possibility of another option is meaningful, and these results give researchers a concrete reason to study the approach more rigorously so that those who may benefit can receive it as safely as possible.

Subject of Research: Stereotactic radiosurgical capsulotomy for treatment-resistant major depression

Article Title: Incisionless radiosurgery shows promise for severe, treatment-resistant depression

Article References: Incisionless radiosurgery shows promise for severe, treatment-resistant depression. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: treatment-resistant depression, stereotactic radiosurgery, capsulotomy, suicidal ideation, radiation oncology, neuromodulation, Beck Depression Inventory, cognitive outcomes, ASTRO, psychiatry, linear accelerator, clinical study